Current Clinical Trials
LSO has completed treatment in a Phase 3 trial in hepatocellular carcinoma and is currently enrolling patients in a Phase 3 trial in colorectal cancer metastatic to the liver, as well as a Phase 2 trial in benign prostatic hyperplasia (BPH).
| Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
| Hepatocellular Carcinoma | ||||
| Metastatic Colorectal Cancer | ||||
| Glioma | ||||
| Benign Prostatic Hyperplasia | ||||
| Age-related Macular Degeneration | ||||
| Peripheral Arterial Disease | ||||
| Coronary Artery Disease | ||||
| Cutaneous Vascular Malformations |
LSO is focusing on a number of cancers for the initial development of Aptocine™: Hepatoma, Metastatic Colorectal Cancer, Prostate Cancer, Pancreatic Cancer, Lung Cancer, Nasopharyngeal Cancer, Head and Neck Cancer, Kidney Cancer, and Glioma/Glioblastoma. Aptocine is also in Phase 2 development for treatment of Benign Prostatic Hyperplasia (BPH), and preclinical development for other non-cancer indications.